Target intelligence / Profile preview

Dedicator of cytokinesis protein 5 (DOCK5)

Target
DOCK5
Molecular classification
Guanine nucleotide exchange factor (GEF), DOCK-A subfamily (DOCK family), Intracellular signalling protein, Rho family GTPase activator
01

Overview

Dedicator of cytokinesis protein 5 (DOCK5) is a large intracellular protein (~180 kDa) encoded by the DOCK5 gene and belongs to the DOCK-A subfamily of guanine nucleotide exchange factors (GEFs) that activate Rho family GTPases, particularly Rac1. DOCK5 is involved in numerous biological processes, including cell migration, adhesion, actin cytoskeleton remodeling, myoblast fusion, bone resorption, mast cell degranulation, and hepatic insulin sensitivity. While its function as an activator of small G-proteins is established, DOCK5 also participates in protein-protein interactions that are independent of its GEF activity. Genetic studies implicate DOCK5 in immune, bone, metabolic, and some cancer-related processes, making it a potential therapeutic target in these disease contexts, though direct drugs have not yet reached clinical application.

Other names
DOCK5Dedicator of cytokinesis protein 5FLJ21034dedicator of cytokinesis protein 5
02

Mechanism of action

Inhibition of guanine nucleotide exchange factor activity for Rac1, thereby modulating downstream signaling and cytoskeletal rearrangement. Blockade of DOCK5 interaction with critical signaling adaptors (e.g., Nck2, Raptor), impacting mast cell degranulation, immune responses, and insulin sensitivity. Targeting the DOCK5-mTORC1-Akt axis to modulate energy balance.

03

Biological functions

Signal transduction via activation of small GTPases, particularly Rac1Regulation of actin cytoskeleton organization and remodelingCell motility and migrationMyoblast fusionOsteoclast adhesion, bone resorption, and survivalMast cell degranulation and immune responseRegulation of hepatic insulin sensitivity and energy balance
04

Disease associations

Cancer (regulation of cell motility, invasion)Bone diseases (abnormal osteoclast regulation; murine lens cataracts)Immune disorders (mast cell degranulation, anaphylactic responses)Metabolic disorders (insulin resistance, energy balance)Li-Fraumeni Syndrome 1 (association)Immunodeficiency 40 (association)
05

Safety considerations

Targeting DOCK5 may affect actin cytoskeleton, cell migration, and immune functions, posing risks such as impaired bone resorption, altered immune responses, or metabolic side effects.Specific safety issues have not been delineated due to lack of clinical studies for DOCK5 inhibitors.
06

Interacting drugs

No approved therapeutic drugs directly targeting DOCK5 are listed in current knowledge or databases. DOCK5 is considered a potential therapeutic target, especially for modulation of Rac1 or metabolic, inflammatory, or cancer pathways, but no specific clinical compounds are reported.
07

Biomarkers

No established biomarkers for patient selection or efficacy monitoring are currently reported. Rac1 activity, mast cell degranulation markers, and hepatic insulin sensitivity may be considered in experimental contexts.

Beyond the preview

Go deeper on Dedicator of cytokinesis protein 5 (DOCK5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dedicator of cytokinesis protein 5 (DOCK5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call